Allied Market Research

2024

23-valent Pneumococcal Polysaccharide Vaccine Market

23-Valent Pneumococcal Polysaccharide Vaccine Market Size, Share, Competitive Landscape and Trend Analysis Report by Dose Type (Single Dose Vial, Pre-filled Syringe) and by Age-Group (Children (2-10 years), Adults (10-64 years), Geriatrics (65 years and above)): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Pneumococcal is an infectious disease caused by the streptococcus pneumoniae bacteria. Pneumococcal may cause different types of illnesses such as ear infection, meningitis, and others. There are vaccines available that can prevent pneumococcal infection such as pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. Pneumococcal polysaccharide vaccines are recommended mostly for adults who suffer from pneumococcal infection.
Increase in geriatric population, rise in the incidence of bacterial infections, and advancements in medical technology are the major factors that drive the market growth. However, stringent government regulations for the approval of vaccines are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA is expected to provide new growth opportunities for the market during the analysis period.

The 23-Valent pneumococcal polysaccharide vaccine market is segmented on the basis of dose type, age-group, and geography. Based on dose type the market is segmented into single dose vial and pre-filled syringe. Based on age-group the market is divided into children (2-10 years), adults (10-64 years), and geriatrics (65 years and above). By geography, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global 23-valent pneumococcal polysaccharide vaccine market, with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report offers a quantitative analysis to assist stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments determines various products available in the market.
  • Key players have been profiled and their strategies thoroughly analyzed to predict the competitive market outlook.

23-Valent Pneumococcal Polysaccharide Vaccine Market Report Highlights

Aspects Details
23-Valent Pneumococcal Polysaccharide Vaccine Market By Dose Type
By Dose Type
  • Single Dose Vial
  • Pre-filled Syringe
23-Valent Pneumococcal Polysaccharide Vaccine Market By Age-Group
By Age-Group
  • Children (2-10 years)
  • Adults (10-64 years)
  • Geriatrics (65 years and above)
23-Valent Pneumococcal Polysaccharide Vaccine Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players
Key Market Players

Serum Institute of India, GlaxoSmithKline Plc, AstraZeneca, Baxter International Inc., .Sanofi S.A., Eli Lilly and Company, Pfizer Inc, Beijing Minhai Biotechnolog, Biogen Inc., Merck & Co.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

23-Valent Pneumococcal Polysaccharide Vaccine Market

Global Opportunity Analysis and Industry Forecast, 2023-2032